DK1476162T3 - Kontrolleret syntese af ziprasidone - Google Patents
Kontrolleret syntese af ziprasidoneInfo
- Publication number
- DK1476162T3 DK1476162T3 DK03702918T DK03702918T DK1476162T3 DK 1476162 T3 DK1476162 T3 DK 1476162T3 DK 03702918 T DK03702918 T DK 03702918T DK 03702918 T DK03702918 T DK 03702918T DK 1476162 T3 DK1476162 T3 DK 1476162T3
- Authority
- DK
- Denmark
- Prior art keywords
- ziprasidone
- controlled synthesis
- synthesis
- controlled
- Prior art date
Links
- 230000015572 biosynthetic process Effects 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 title 1
- 229960000607 ziprasidone Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Liquid Crystal Substances (AREA)
- Indole Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35880602P | 2002-02-20 | 2002-02-20 | |
US35903802P | 2002-02-21 | 2002-02-21 | |
US36045902P | 2002-02-27 | 2002-02-27 | |
PCT/IB2003/000642 WO2003070246A1 (en) | 2002-02-20 | 2003-02-17 | Controlled synthesis of ziprasidone and compositions thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1476162T3 true DK1476162T3 (da) | 2007-07-02 |
Family
ID=27761437
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK03702918T DK1476162T3 (da) | 2002-02-20 | 2003-02-17 | Kontrolleret syntese af ziprasidone |
Country Status (41)
Country | Link |
---|---|
EP (1) | EP1476162B1 (de) |
JP (1) | JP4554938B2 (de) |
KR (1) | KR100773622B1 (de) |
CN (2) | CN101735212A (de) |
AP (1) | AP2004003103A0 (de) |
AR (1) | AR038563A1 (de) |
AT (1) | ATE359787T1 (de) |
AU (2) | AU2003206035A1 (de) |
BR (1) | BR0307833A (de) |
CA (1) | CA2475302C (de) |
CO (1) | CO5611138A2 (de) |
CY (1) | CY1106467T1 (de) |
DE (1) | DE60313289T2 (de) |
DK (1) | DK1476162T3 (de) |
EA (1) | EA007866B1 (de) |
EC (1) | ECSP045239A (de) |
ES (1) | ES2283745T3 (de) |
GE (1) | GEP20074030B (de) |
GT (1) | GT200300040A (de) |
HR (1) | HRP20040711A2 (de) |
IL (1) | IL163277A (de) |
IS (1) | IS7344A (de) |
MA (1) | MA27177A1 (de) |
MX (1) | MXPA04006993A (de) |
MY (1) | MY139523A (de) |
NO (2) | NO20043902L (de) |
NZ (1) | NZ534443A (de) |
OA (1) | OA12774A (de) |
PA (1) | PA8567001A1 (de) |
PE (1) | PE20030942A1 (de) |
PL (1) | PL372238A1 (de) |
PT (1) | PT1476162E (de) |
RS (1) | RS60404A (de) |
SI (1) | SI1476162T1 (de) |
SV (1) | SV2004001485A (de) |
TN (1) | TNSN04159A1 (de) |
TW (1) | TW200307546A (de) |
UA (1) | UA77057C2 (de) |
UY (1) | UY27668A1 (de) |
WO (1) | WO2003070246A1 (de) |
ZA (1) | ZA200406276B (de) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001066521A1 (en) | 2000-03-06 | 2001-09-13 | Acadia Pharmaceuticals, Inc. | Azacyclic compounds for use in the treatment of serotonin related diseases |
WO2003057698A2 (en) | 2001-12-28 | 2003-07-17 | Acadia Pharmaceuticals, Inc. | Spiroazacyclic compounds as monoamine receptor modulators |
IL165907A0 (en) | 2002-06-24 | 2006-01-15 | Acadia Pharm Inc | N-substituted piperidine derivatives as serotonin receptor agents |
US7253186B2 (en) | 2002-06-24 | 2007-08-07 | Carl-Magnus Andersson | N-substituted piperidine derivatives as serotonin receptor agents |
US7538222B2 (en) | 2002-06-24 | 2009-05-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
WO2004050655A1 (en) * | 2002-12-04 | 2004-06-17 | Dr. Reddy's Laboratories Limited | Polymorphic forms of ziprasidone and its hydrochloride |
AU2003300814A1 (en) | 2002-12-04 | 2004-06-23 | Dr. Reddy's Laboratories Inc. | Polymorphic forms of ziprasidone and its hydrochloride |
PT1587789E (pt) | 2003-01-16 | 2008-12-16 | Acadia Pharm Inc | Agonistas inversos selectivos para receptores 2a/2c da serotonina como agentes terapêuticos para doenças neurodegenerativas |
WO2004083192A1 (en) | 2003-03-17 | 2004-09-30 | Teva Pharmaceutical Industries Ltd. | Polymorphis of valsartan |
US7199144B2 (en) | 2003-04-21 | 2007-04-03 | Teva Pharmaceuticals Industries, Ltd. | Process for the preparation of valsartan and intermediates thereof |
WO2004094392A1 (en) * | 2003-04-21 | 2004-11-04 | Teva Pharmaceutical Industries Ltd. | Process for the preparation of valsartan |
WO2005016325A2 (en) | 2003-06-03 | 2005-02-24 | Teva Pharmaceutical Industries Ltd. | CRISTALLINE ZIPRASIDONE HCl AND PROCESSES FOR PREPARATION THEREOF |
CA2543805A1 (en) | 2003-10-24 | 2005-05-06 | Gideon Pilarsky | Processes for preparation of ziprasidone |
US20050197347A1 (en) * | 2003-12-18 | 2005-09-08 | Judith Aronhime | Polymorphic form B2 of ziprasidone base |
ATE451367T1 (de) | 2004-02-27 | 2009-12-15 | Ranbaxy Lab Ltd | Verfahren zur herstellung von ziprasidon |
CA2467538C (en) | 2004-05-14 | 2010-08-24 | Apotex Pharmachem Inc. | New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same |
US7820695B2 (en) | 2004-05-21 | 2010-10-26 | Acadia Pharmaceuticals, Inc. | Selective serotonin receptor inverse agonists as therapeutics for disease |
CA2471219A1 (en) | 2004-06-14 | 2005-12-14 | Apotex Pharmachem Inc. | Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride) |
CN101035759B (zh) | 2004-09-27 | 2011-06-15 | 阿卡蒂亚药品公司 | N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n’-(4-(2-甲基丙氧基)苯基甲基)脲及其酒石酸盐的合成和晶形 |
US7790899B2 (en) | 2004-09-27 | 2010-09-07 | Acadia Pharmaceuticals, Inc. | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
ES2250000B1 (es) * | 2004-09-29 | 2007-06-01 | Medichem, S.A. | Procedimiento para la preparacion de ziprasidona. |
ES2250001B1 (es) * | 2004-09-29 | 2007-06-01 | Medichem, S.A. | Proceso para la purificacion de ziprasidona. |
EP1841764A1 (de) * | 2005-01-27 | 2007-10-10 | Hetero Drugs Limited | Verfahren für ziprasidon unter verwendung neuer zwischenprodukte |
ITMI20052216A1 (it) * | 2005-11-18 | 2007-05-19 | Dipharma Spa | Procedimento per la preparazione di ziprasidone |
CN100491375C (zh) * | 2006-07-01 | 2009-05-27 | 浙江美诺华药物化学有限公司 | 一种齐拉西酮的制备方法 |
ES2423485T3 (es) | 2007-03-19 | 2013-09-20 | Acadia Pharmaceuticals Inc. | Asociaciones de agonistas y antagonistas inversos 5-HT2A con antipsicóticos |
CN102234273B (zh) * | 2010-04-21 | 2015-08-05 | 上海医药工业研究院 | 甲磺酸齐拉西酮半水合物及其制备方法 |
CN102234272A (zh) * | 2010-04-21 | 2011-11-09 | 上海医药工业研究院 | 盐酸齐拉西酮半水合物的制备方法 |
SI3325444T1 (sl) | 2015-07-20 | 2021-11-30 | Acadia Pharmaceuticals Inc. | Postopki za pripravo N-(4-fluorobenzil)-N-(1-metilpiperidin-4-il)-N'- (4-(2-metilpropiloksi)fenilmetil)karbamida in njegove tartratne soli in polimorfne oblike C |
US10953000B2 (en) | 2016-03-25 | 2021-03-23 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome P450 modulators |
WO2017165635A1 (en) | 2016-03-25 | 2017-09-28 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome p450 modulators |
EP3558311A1 (de) | 2016-12-20 | 2019-10-30 | Acadia Pharmaceuticals Inc. | Pimavanserin allein oder in kombination zur verwendung in der behandlung von morbus-alzheimer-psychose |
CN108239085A (zh) * | 2016-12-26 | 2018-07-03 | 四川科瑞德凯华制药有限公司 | 一种甲磺酸齐拉西酮的纯化及制备方法 |
US11135211B2 (en) | 2017-04-28 | 2021-10-05 | Acadia Pharmaceuticals Inc. | Pimavanserin for treating impulse control disorder |
US20210077479A1 (en) | 2017-08-30 | 2021-03-18 | Acadia Pharmaceuticals Inc. | Formulations of pimavanserin |
CN112724066B (zh) * | 2021-02-04 | 2022-10-21 | 海南鑫开源医药科技有限公司 | 一种盐酸齐拉西酮中间体中的二卤杂质及其制备方法 |
CN116046966A (zh) * | 2023-01-17 | 2023-05-02 | 北京协和建昊医药技术开发有限责任公司 | 一种流动相配置装置及其配置方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4831031A (en) | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
US5338846A (en) * | 1992-08-26 | 1994-08-16 | Pfizer Inc. | Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt |
US5206366A (en) * | 1992-08-26 | 1993-04-27 | Pfizer Inc. | Process for preparing aryl piperazinyl-heterocyclic compounds |
US5312925A (en) | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
US5359068A (en) * | 1993-06-28 | 1994-10-25 | Pfizer Inc. | Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one |
CN1071324C (zh) | 1995-11-07 | 2001-09-19 | 辉瑞大药厂 | 制备3-(1-哌嗪基)-1,2-苯并异噻唑的方法和中间体 |
SI0904273T1 (en) * | 1996-05-07 | 2003-08-31 | Pfizer Inc. | Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one (=ziprasidone), its preparation and its use as dopamine d2 antagonist |
TW491847B (en) | 1996-05-07 | 2002-06-21 | Pfizer | Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one |
IL127497A (en) * | 1997-12-18 | 2002-07-25 | Pfizer Prod Inc | Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders |
US6150366A (en) * | 1998-06-15 | 2000-11-21 | Pfizer Inc. | Ziprasidone formulations |
-
2003
- 2003-02-14 UY UY27668A patent/UY27668A1/es not_active Application Discontinuation
- 2003-02-17 JP JP2003569202A patent/JP4554938B2/ja not_active Expired - Fee Related
- 2003-02-17 OA OA1200400216A patent/OA12774A/en unknown
- 2003-02-17 EP EP03702918A patent/EP1476162B1/de not_active Revoked
- 2003-02-17 AP APAP/P/2004/003103A patent/AP2004003103A0/en unknown
- 2003-02-17 AT AT03702918T patent/ATE359787T1/de active
- 2003-02-17 CN CN200910261963A patent/CN101735212A/zh active Pending
- 2003-02-17 PL PL03372238A patent/PL372238A1/xx not_active Application Discontinuation
- 2003-02-17 UA UA20040806969A patent/UA77057C2/uk unknown
- 2003-02-17 KR KR1020047012980A patent/KR100773622B1/ko not_active IP Right Cessation
- 2003-02-17 AU AU2003206035A patent/AU2003206035A1/en not_active Abandoned
- 2003-02-17 PT PT03702918T patent/PT1476162E/pt unknown
- 2003-02-17 RS YU60404A patent/RS60404A/sr unknown
- 2003-02-17 WO PCT/IB2003/000642 patent/WO2003070246A1/en active Application Filing
- 2003-02-17 CA CA002475302A patent/CA2475302C/en not_active Expired - Fee Related
- 2003-02-17 DK DK03702918T patent/DK1476162T3/da active
- 2003-02-17 ES ES03702918T patent/ES2283745T3/es not_active Expired - Lifetime
- 2003-02-17 DE DE60313289T patent/DE60313289T2/de not_active Revoked
- 2003-02-17 MX MXPA04006993A patent/MXPA04006993A/es not_active Application Discontinuation
- 2003-02-17 SI SI200330811T patent/SI1476162T1/sl unknown
- 2003-02-17 EA EA200400815A patent/EA007866B1/ru not_active IP Right Cessation
- 2003-02-17 BR BR0307833-7A patent/BR0307833A/pt not_active IP Right Cessation
- 2003-02-17 CN CNA038042460A patent/CN1635892A/zh active Pending
- 2003-02-17 PE PE2003000168A patent/PE20030942A1/es not_active Application Discontinuation
- 2003-02-17 NZ NZ534443A patent/NZ534443A/en not_active IP Right Cessation
- 2003-02-17 GE GE5684A patent/GEP20074030B/en unknown
- 2003-02-18 TW TW092103292A patent/TW200307546A/zh unknown
- 2003-02-18 AR ARP030100527A patent/AR038563A1/es unknown
- 2003-02-18 GT GT200300040A patent/GT200300040A/es unknown
- 2003-02-18 MY MYPI20030564A patent/MY139523A/en unknown
- 2003-02-19 SV SV2003001485A patent/SV2004001485A/es not_active Application Discontinuation
- 2003-02-20 PA PA20038567001A patent/PA8567001A1/es unknown
-
2004
- 2004-07-05 IS IS7344A patent/IS7344A/is unknown
- 2004-07-29 IL IL163277A patent/IL163277A/en unknown
- 2004-08-04 HR HRP20040711 patent/HRP20040711A2/xx not_active Application Discontinuation
- 2004-08-05 ZA ZA200406276A patent/ZA200406276B/en unknown
- 2004-08-13 CO CO04079019A patent/CO5611138A2/es unknown
- 2004-08-17 MA MA27827A patent/MA27177A1/fr unknown
- 2004-08-19 TN TNP2004000159A patent/TNSN04159A1/fr unknown
- 2004-08-19 EC EC2004005239A patent/ECSP045239A/es unknown
- 2004-09-17 NO NO20043902A patent/NO20043902L/no not_active Application Discontinuation
-
2007
- 2007-05-10 CY CY20071100629T patent/CY1106467T1/el unknown
-
2009
- 2009-05-21 AU AU2009202008A patent/AU2009202008A1/en not_active Ceased
-
2010
- 2010-04-22 NO NO20100584A patent/NO20100584L/no not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1476162T3 (da) | Kontrolleret syntese af ziprasidone | |
DK1778618T3 (da) | Syntese af triethylentetraminer | |
DK1438306T3 (da) | Derivater af UK-2A | |
DK1802579T3 (da) | Derivater af 3-arylaminopyridin | |
DK1658295T3 (da) | Regioselektiv syntese af CCI-779 | |
IS7007A (is) | Kristallaform af asiþrómýsíni | |
DK1360169T3 (da) | Succinatsalt af O-desmethyl-venlafaxin | |
DK2377869T3 (da) | Syntese af Bortezomib | |
DK1587542T3 (da) | Anvendelse af anti-CD100-antistoffer | |
DK1470732T3 (da) | Fremskaffelse af lokaliseringsinformation | |
DK1663991T3 (da) | Selektiv syntese af CF3-substituerede pyrimidiner | |
IS7833A (is) | Efnasambönd með sameinaða heteróhringi | |
DK1516540T3 (da) | Anvendelse af vitamin D-forbindelser | |
ATE364610T1 (de) | Kristalline polymorphe form von irinotecan- hyrochlorid | |
ATE356124T1 (de) | Hydroxyalkylsubstituierte pyrido-7-pyrimidin-7- one | |
DE502004011575D1 (de) | Verwendung von Dioldimerfettsäureestern | |
DE50302584D1 (de) | Stereomikroskop | |
DE50302514D1 (de) | Stereomikroskop | |
DK1578774T3 (da) | Oprensning af immunoglobuliner | |
DE60332980D1 (de) | Sprachsynthese | |
DK1565563T3 (da) | Enzymatisk syntese af polyolacrylater | |
DE10394144D2 (de) | Duschvorrichtung | |
DK1567524T3 (da) | Thia-epothilonderivater til behandling af cancer | |
DK1730109T3 (da) | Syntese af pyrrol-2-carbonitriler | |
DK1535612T3 (da) | Behandling af hyperurikæmi |